333 related articles for article (PubMed ID: 34948100)
21. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.
Lee SJ; Park HJ; Kim YH; Kim BY; Jin HS; Kim HJ; Han JH; Yim H; Jeong SY
Int J Mol Med; 2012 Aug; 30(2):443-50. PubMed ID: 22664653
[TBL] [Abstract][Full Text] [Related]
22. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
23. Schwann cell lines derived from malignant peripheral nerve sheath tumors respond abnormally to platelet-derived growth factor-BB.
Dang I; DeVries GH
J Neurosci Res; 2005 Feb; 79(3):318-28. PubMed ID: 15602756
[TBL] [Abstract][Full Text] [Related]
24. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.
Jessen WJ; Miller SJ; Jousma E; Wu J; Rizvi TA; Brundage ME; Eaves D; Widemann B; Kim MO; Dombi E; Sabo J; Hardiman Dudley A; Niwa-Kawakita M; Page GP; Giovannini M; Aronow BJ; Cripe TP; Ratner N
J Clin Invest; 2013 Jan; 123(1):340-7. PubMed ID: 23221341
[TBL] [Abstract][Full Text] [Related]
25. Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors.
Bai RY; Esposito D; Tam AJ; McCormick F; Riggins GJ; Wade Clapp D; Staedtke V
Gene Ther; 2019 Jun; 26(6):277-286. PubMed ID: 31127187
[TBL] [Abstract][Full Text] [Related]
26. Neurofibromatosis type 1 (NF1) tumor suppressor, neurofibromin, regulates the neuronal differentiation of PC12 cells via its associating protein, CRMP-2.
Patrakitkomjorn S; Kobayashi D; Morikawa T; Wilson MM; Tsubota N; Irie A; Ozawa T; Aoki M; Arimura N; Kaibuchi K; Saya H; Araki N
J Biol Chem; 2008 Apr; 283(14):9399-413. PubMed ID: 18218617
[TBL] [Abstract][Full Text] [Related]
27. The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways.
Shapira S; Barkan B; Friedman E; Kloog Y; Stein R
Cell Death Differ; 2007 May; 14(5):895-906. PubMed ID: 17096025
[TBL] [Abstract][Full Text] [Related]
28. Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1.
Hirata Y; Brems H; Suzuki M; Kanamori M; Okada M; Morita R; Llano-Rivas I; Ose T; Messiaen L; Legius E; Yoshimura A
J Biol Chem; 2016 Feb; 291(7):3124-34. PubMed ID: 26635368
[TBL] [Abstract][Full Text] [Related]
29. Neurofibromatosis type 1 alternative splicing is a key regulator of Ras/ERK signaling and learning behaviors in mice.
Nguyen HT; Hinman MN; Guo X; Sharma A; Arakawa H; Luo G; Lou H
Hum Mol Genet; 2017 Oct; 26(19):3797-3807. PubMed ID: 28934393
[TBL] [Abstract][Full Text] [Related]
30. Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.
Dilworth JT; Wojtkowiak JW; Mathieu P; Tainsky MA; Reiners JJ; Mattingly RR; Hancock CN
Cancer Biol Ther; 2008 Dec; 7(12):1938-46. PubMed ID: 18927496
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors.
Ki DH; He S; Rodig S; Look AT
Oncogene; 2017 Feb; 36(8):1058-1068. PubMed ID: 27477693
[TBL] [Abstract][Full Text] [Related]
32. Preventative Effect of Mebendazole against Malignancies in Neurofibromatosis 1.
Staedtke V; Gray-Bethke T; Riggins GJ; Bai RY
Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32650362
[TBL] [Abstract][Full Text] [Related]
33. Ras-Mek-Erk signaling regulates Nf1 heterozygous neointima formation.
Stansfield BK; Bessler WK; Mali R; Mund JA; Downing BD; Kapur R; Ingram DA
Am J Pathol; 2014 Jan; 184(1):79-85. PubMed ID: 24211110
[TBL] [Abstract][Full Text] [Related]
34. Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.
Sohier P; Luscan A; Lloyd A; Ashelford K; Laurendeau I; Briand-Suleau A; Vidaud D; Ortonne N; Pasmant E; Upadhyaya M
Genes Chromosomes Cancer; 2017 May; 56(5):421-426. PubMed ID: 28124441
[TBL] [Abstract][Full Text] [Related]
35. Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.
Kazmi SJ; Byer SJ; Eckert JM; Turk AN; Huijbregts RP; Brossier NM; Grizzle WE; Mikhail FM; Roth KA; Carroll SL
Am J Pathol; 2013 Mar; 182(3):646-67. PubMed ID: 23321323
[TBL] [Abstract][Full Text] [Related]
36. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
37. MiR-27a-3p/miR-27b-3p Promotes Neurofibromatosis Type 1 via Targeting of NF1.
Lu H; Liu P; Pang Q
J Mol Neurosci; 2021 Nov; 71(11):2353-2363. PubMed ID: 33570696
[TBL] [Abstract][Full Text] [Related]
38. Classic Ras Proteins Promote Proliferation and Survival via Distinct Phosphoproteome Alterations in Neurofibromin-Null Malignant Peripheral Nerve Sheath Tumor Cells.
Brossier NM; Prechtl AM; Longo JF; Barnes S; Wilson LS; Byer SJ; Brosius SN; Carroll SL
J Neuropathol Exp Neurol; 2015 Jun; 74(6):568-86. PubMed ID: 25946318
[TBL] [Abstract][Full Text] [Related]
39. ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms.
Longo JF; Brosius SN; Black L; Worley SH; Wilson RC; Roth KA; Carroll SL
Cell Commun Signal; 2019 Jul; 17(1):74. PubMed ID: 31291965
[TBL] [Abstract][Full Text] [Related]
40. A novel mutation in NF1 gene of patient with Neurofibromatosis type 1: A case report and functional study.
Zhang T; Jia C; Dong Z; Li C; Lu W
Mol Genet Genomic Med; 2021 May; 9(5):e1643. PubMed ID: 33764694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
